Nektar Therapeutics Deferred Compensation Arrangement with Individual, Contributions by Employer
Nektar Therapeutics (NKTR) reported Deferred Compensation Arrangement with Individual, Contributions by Employer of $12.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer · last filed 2026-03-13
- Nektar Therapeutics deferred compensation arrangement with individual, contributions by employer for fiscal 2025 was $12.00K, a 0.00% change from fiscal 2024.
- Nektar Therapeutics deferred compensation arrangement with individual, contributions by employer for fiscal 2024 was $12.00K, a 99.90% decline from fiscal 2023.
- Nektar Therapeutics deferred compensation arrangement with individual, contributions by employer for fiscal 2023 was $12.00M, a 0.00% change from fiscal 2022.
- Nektar Therapeutics deferred compensation arrangement with individual, contributions by employer for fiscal 2022 was $12.00M, a 100.00% increase from fiscal 2021.
| Period end | Deferred Compensation Arrangement with Individual, Contributions by Employer 12 month | Deferred Compensation Arrangement with Individual, Contributions by Employer 12 month as first filed |
|---|---|---|
| 2025-12-31 | $12.00K 10-K · filed 2026-03-13 | |
| 2024-12-31 | $12.00K 10-K · filed 2026-03-13 | $12.00M 10-K · filed 2025-03-14 |
| 2023-12-31 | $12.00M 10-K · filed 2025-03-14 | |
| 2022-12-31 | $12.00M 10-K · filed 2024-03-05 | $12.00K 10-K · filed 2023-02-28 |
| 2021-12-31 | $6.00M 10-K · filed 2024-03-05 | $6.00K 10-K · filed 2022-03-01 |
| 2020-12-31 | $6.00K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $6.00K 10-K · filed 2020-02-28 | |
| 2018-12-31 | $6.00K 10-K · filed 2019-03-01 | |
| 2017-12-31 | $4.00K 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |